<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780793</url>
  </required_header>
  <id_info>
    <org_study_id>AOM 07127</org_study_id>
    <nct_id>NCT00780793</nct_id>
  </id_info>
  <brief_title>Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study</brief_title>
  <acronym>STRASS</acronym>
  <official_title>Effect of TNF-blocker Injections Spacing on Rheumatoid Arthritis Inflammatory Activity in Patients in Clinical Remission or Low Disease Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Society of Rheumatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remission is nowadays the recommended therapeutic objective in rheumatoid arthritis. Once&#xD;
      this objective is achieved thanks to TNF-blockers, the optimal therapeutic strategy remains&#xD;
      unclear, either therapeutic maintenance or progressive DMARD tapering (with a non quantified&#xD;
      risk of disease flare).&#xD;
&#xD;
      STRASS is a 2-arm randomized controlled trial aiming to compare these 2 strategies (DMARD&#xD;
      maintenance or progressive spacing of TNF-blocker injections) in terms of remission&#xD;
      maintenance, relapse risk, safety issues and economic consequences during 18 months.&#xD;
&#xD;
      The inclusion period is 18 months, between September 2008 and February 2010.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Clinical remission is the therapeutic objective in rheumatoid arthritis, as recommended by&#xD;
      professional practice guidelines. Once this objective is achieved with subcutaneous&#xD;
      TNF-blockers, the maintenance of such treatments - highly efficacious but expensive and&#xD;
      potentially toxic - is debated. To date, no reliable data are available to estimate the risk&#xD;
      - benefice ratio associated with either their maintenance or their tapering.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      In RA patients in remission, the study aims:&#xD;
&#xD;
        1. To compare RA inflammatory activity based on repeated measures of the Disease Activity&#xD;
           Score (DAS) depending on 2 therapeutic schemes: (M) maintenance of unchanged&#xD;
           TNF-blockers or (S) tapering of TNF-blocker doses by progressive spacing of subcutaneous&#xD;
           injections according to a predefined algorithm;&#xD;
&#xD;
        2. To estimate the cost - effectiveness ratio of TNF-blocker spacing as compared to&#xD;
           TNF-blocker maintenance.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Patients aged 18 or more, diagnosed with RA according to the 1987 ACR classification&#xD;
           criteria;&#xD;
&#xD;
        -  RA treated with subcutaneous TNF-blockers (etanercept or adalimumab) at stable and&#xD;
           standard dosage for 1 year or more, as monotherapy or associated with stable&#xD;
           conventional DMARD;&#xD;
&#xD;
        -  RA in clinical remission, defined as a stable DAS28 ≤ 2.6 for 6 months or more, without&#xD;
           any structural damage progression on X-rays (local reading by the treating&#xD;
           rheumatologist);&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Treatment with steroids;&#xD;
&#xD;
        -  progressing disease on X-rays during the year preceding the trial;&#xD;
&#xD;
        -  surgery planed in the 18 coming months;&#xD;
&#xD;
        -  pregnancy;&#xD;
&#xD;
        -  on-going neoplastic disease;&#xD;
&#xD;
        -  other auto-immune disorders different from RA;&#xD;
&#xD;
        -  inability to speak or understand French;&#xD;
&#xD;
        -  absence of signed informed consent;&#xD;
&#xD;
        -  absence of medical insurance coverage.&#xD;
&#xD;
      Sample size calculation: 250 patients, 125 for each arm.&#xD;
&#xD;
      Centers: 22 inclusion centers in France.&#xD;
&#xD;
      Research duration: 3 years. Participation duration for each patient: 18 months. Inclusion&#xD;
      period duration: 18 months (Sep 2008 - Feb 2010).&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Equivalence trial, prospective, randomized, controlled versus usual care, patients remaining&#xD;
      blinded of the tested hypotheses.&#xD;
&#xD;
      Investigators assessing disease activity remain blind of the protocol arm. The statistical&#xD;
      analysis will be based on a mixed linear model taking into account repeated data.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Computer-assisted randomization (CleanWeb software) by blocks of unequal size, stratified on&#xD;
      inclusion centers and TNF-blocker molecule.&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      RA inflammatory activity over 18 months estimated by DAS28 repeated measures.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  RA inflammatory activity over 18 months estimated by DAS44 repeated measures;&#xD;
&#xD;
        -  Cost - Effectiveness ratio calculated as: (CostMaintenance - CostSpacing) /&#xD;
           (EfficacyMaintenance - EfficacySpacing);&#xD;
&#xD;
        -  Relapse rate over 18 months based on Kaplan Meier survival analysis;&#xD;
&#xD;
        -  Functional impairment based on HAQ index;&#xD;
&#xD;
        -  Health-related quality of life on SF-36;&#xD;
&#xD;
        -  Utility based on EQ-5D instrument;&#xD;
&#xD;
        -  Structural damage progression over 18 months assessed with the van der HEIJDE-modified&#xD;
           Sharp score (SHS);&#xD;
&#xD;
        -  Safety;&#xD;
&#xD;
        -  Determinants of maintained remission or relapse after TNF-blocker injection spacing.&#xD;
&#xD;
      Research time sheet:&#xD;
&#xD;
      Clinical, biological and imaging follow-up is based on guidelines-recommended RA follow-up.&#xD;
&#xD;
      Biological work-ups specifically dedicated to the research represent 80 mL. The others are&#xD;
      part of usual care and may be performed in non-hospital laboratories.&#xD;
&#xD;
      Expected results and perspectives:&#xD;
&#xD;
      The trial aims to test the feasibility and the risk - benefit ratio of a step-down strategy&#xD;
      for TNF-blockers in the course of RA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RA inflammatory activity over 18 months based on repeated DAS28 measures</measure>
    <time_frame>over 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RA inflammatory activity over 18 months estimated by DAS44 repeated measures</measure>
    <time_frame>over 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost - Effectiveness ratio calculated as: (CostMaintenance - CostSpacing) / (EfficacyMaintenance - EfficacySpacing);</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate over 18 months based on Kaplan Meier survival analysis</measure>
    <time_frame>over 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional impairment based on HAQ index</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life on SF-36</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility based on EQ-5D instrument</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural damage progression over 18 months assessed with the van der HEIJDE-modified Sharp score (SHS)</measure>
    <time_frame>over 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determinants of maintained remission or relapse after TNF-blocker injection spacing</measure>
    <time_frame>during teh study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1-M : Maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 -S : Spacing of TNF-blocker injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spacing of TNF-blocker injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progressive spacing of TNF-blocker injections</intervention_name>
    <description>Experimental arm&#xD;
Progressive spacing of TNF-blocker injections according to the following algorithm :&#xD;
if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1&#xD;
if DAS28 &gt; 2.6 and DAS28 change ≤ 0.6: continue at step N&#xD;
if DAS28 &gt; 2.6 and DAS28 change &gt; 0.6 : return to step N-1 (relapse as defined by the European expert consensus).&#xD;
Step 0 (inclusion) :&#xD;
Adalimumab 40 mg / 14 days&#xD;
Etanercept 50 mg / 7 days&#xD;
Step 1 :&#xD;
Adalimumab 40 mg / 21 days&#xD;
Etanercept 50 mg / 10 days&#xD;
Step 2 :&#xD;
Adalimumab 40 mg / 28 days&#xD;
Etanercept 50 mg / 14 days&#xD;
Step 3 :&#xD;
Adalimumab 40 mg / 42 days&#xD;
Etanercept 50 mg / 21 days&#xD;
Step 4 :&#xD;
TNF-blocker stop</description>
    <arm_group_label>2 -S : Spacing of TNF-blocker injections</arm_group_label>
    <other_name>Spacing (S)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMARD maintenance</intervention_name>
    <description>DMARD maintenance</description>
    <arm_group_label>1-M : Maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 or more, diagnosed with RA according to the 1987 ACR classification&#xD;
             criteria;&#xD;
&#xD;
          -  RA treated with subcutaneous TNF-blockers (étanercept or adalimumab) at stable and&#xD;
             standard dosage for 1 year or more, as monotherapy or associated with stable&#xD;
             conventional DMARD;&#xD;
&#xD;
          -  RA in clinical remission, defined as a stable DAS28 ≤ 2.6 for 6 months or more,&#xD;
             without any structural damage progression on X-rays (local reading by the treating&#xD;
             rheumatologist);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with steroids;&#xD;
&#xD;
          -  progressing disease on X-rays during the year preceding the trial;&#xD;
&#xD;
          -  surgery planed in the 18 coming months;&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  on-going neoplastic disease;&#xD;
&#xD;
          -  other auto-immune disorders different from RA;&#xD;
&#xD;
          -  inability to speak or understand French;&#xD;
&#xD;
          -  absence of signed informed consent;&#xD;
&#xD;
          -  absence of medical insurance coverage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Fautrel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de rhumatologie / Groupe hospitalier Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 27, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Remission</keyword>
  <keyword>Therapeutic strategy</keyword>
  <keyword>DMARDs</keyword>
  <keyword>Biological agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tumor Necrosis Factor Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

